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 Abstract  
Non-adherence to inhaled medication leads to poor asthma control and increased health care 
utilization. Many studies exploring adherence determinants have been conducted, but summaries of the 
evidence are scarce. We performed a systematic review of observational research on determinants of 
asthma inhaler adherence among adults. 
 
We searched for articles in English reporting quantitative observational studies on inhaler adherence 
correlates among adults in developed countries, published in EMBASE, Medline, PsychInfo, and 
PsychArticles in 1990-2014. Two coders independently assessed eligibility, extracted data, and assessed 
study quality. Results were summarized qualitatively into social and economic, health care, therapy, 
condition, and patient-related factors. 
 
The 51 studies included mainly examined patient-related factors and found consistent links between 
adherence and stronger inhaler necessity beliefs, and possibly older age. There was limited evidence on 
the relevance of other determinants, partly due to study heterogeneity regarding the types of 
determinants examined. Methodological quality varied considerably and studies performed generally 
poorly on their definitions of variables and measures, risk of bias, sample size, and data analysis. 
 
A broader adoption of common methodological standards and health behaviour theories is needed 
before a cumulative science on the determinants of adherence to asthma inhalers among adults can 
develop further. 
The introduction of inhaled medication as primary asthma treatment has led to substantial 
improvements in asthma control (1,2). However, uncontrolled asthma is still common and represents a 
considerable burden to patients and society (3,4). An important reason for poor asthma control and 
consequently increased health care expenditure, is suboptimal adherence to the prescribed regimen (5–
7). To date, few adherence interventions evaluated in asthma treatment have been found (cost-
)effective (8–10). A systematic review of observational evidence on adherence determinants could help 
identify the patients most at-risk for non-adherence and the key drivers of non-adherence that can be 
modified in adherence interventions.  
Although several narrative reviews on determinants of adherence to asthma medication have 
been conducted (11–18), only two systematic reviews on observational research are available. Both 
examined adherence to inhaled corticosteroids (ICs): one focused on children (19), the other exclusively 
evaluated the role of illness and treatment perceptions in adults (20). Neither examined the quality of 
the methodology of included studies, which is important in interpreting empirical evidence (21–23).  To 
our knowledge, no comprehensive systematic review of factors related to adherence to inhaled 
medication in adults with asthma has been published to date. 
The objective of this study was to synthesize the current observational evidence on 
determinants of inhaler adherence in asthmatic adults through a systematic review, including a critical 
appraisal of the methodological quality of the studies, and develop recommendations for future 
research in this domain. 
Methods 
Literature search and study selection 
EMBASE, Medline, PsychInfo, and PsychArticles were searched for manuscripts published between 1 
January 1990 and 26 June 2014 with keywords on asthma, adherence, persistence, compliance, 
concordance, determinant, cause, influence, barrier, and facilitator (see Supplementary Material 1). 
Eligibility was determined using the following criteria: peer-reviewed article in English, reporting an 
empirical quantitative observational study (cross-sectional or longitudinal designs), presenting results on 
adult (>18 years) asthma patients living in developed countries (24), investigating one or more 
predictors of adherence to inhaled asthma medication, and describing the adherence measurement 
procedure. The selection was initially based on the information in the title and abstract; if inconclusive, 
the entire manuscript was examined. Two reviewers (AD and OC) examined the search results 
independently. Disagreements were reconciled by a third reviewer (MdB) and through consensus.  
Data extraction 
Two coders (AD and OC) extracted information on study characteristics (objectives, methodology, 
country, language, setting, sample size, age, gender, asthma severity and type of inhaled medication 
studied), adherence behaviours and determinants (definition, measurement and psychometrics), and 
statistical data (type of analysis and results reported). The data extraction procedure was piloted on 
articles not included in the review. Each coder extracted data from 50% of papers. The accuracy of the 
recorded information was verified by the other coder, and disagreements were discussed and 
reconciled. 
Quality rating 
Two coders (AD and GH) rated methodological quality based on six criteria adapted from the STROBE 
guidelines which are considered key requirements for observational studies (25,26). Scoring was 
performed on a 4-level response format, from no information reported to adequate reporting of 
appropriately used methodology (coding sheet in Supplementary Material 2). The studies were judged 
on methods clarity and pertinence in six domains: (1) selection of participants (e.g., sampling strategy, 
eligibility criteria and methods for assessing eligibility), (2) definition of variables (i.e., outcomes, 
determinants and confounders), (3) description of data sources and measurement procedures for all 
variables, (4) addressing potential sources of bias (e.g., medical surveillance, recall, or response bias), (5) 
sample size justification (e.g., power analysis, multiple comparisons correction), and (6) data analysis 
(e.g., data preparation, controlling for confounding and data collection, sensitivity analyses). 
Disagreements were discussed and reconciled. 
Data analysis 
The data on study characteristics and adherence measurement were summarized descriptively. The 
results on the relationships between adherence determinants and behaviours were grouped separately 
for reliever (e.g., short-acting beta agonists; SABA) and controller (e.g., ICs) medication as they relate to 
different recommendations (daily versus as needed use). Controller adherence was examined separately 
for the three stages of adherence (27): starting treatment (initiation), accuracy of medication use 
(implementation), and continuing treatment (persistence). Determinants were classified using the five 
dimensions of the World Health Organization (WHO) taxonomy (26,27): (1) social and economic, (2) 
health care team and system-related, (3) condition-related, (4) therapy-related, and (5) patient-related 
factors, each with additional sub-dimensions. We summarized results regarding the statistical 
significance and direction of relationships for all studies. Adjusted results obtained by multivariate 
analyses were prioritized over unadjusted when available. 
Metric properties of the 6 study quality items were investigated. Reliability was assessed by 
estimating inter-rater agreement with weighted Kappa, considered appropriate for ordinal scores (28), 
and interpreted based on established thresholds for poor, fair, moderate, good, and excellent 
agreement (.20, .40, .60, and .80 respectively) (29). Mokken Scaling and correlational analyses were 
performed on consensus scores to evaluate structural validity and examine the relationships between 
criteria.  Total quality scores were computed adding scores on the criteria with adequate metric 
properties; studies were classified as higher versus lower quality via median split.  Statistical analyses 
were performed with IBM SPSS Statistics 21 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, 
Version 21.0. Armonk, NY: IBM Corp.) and R (30) mokken package (31,32). 
Results 
Study selection 
The database search identified 2878 unique articles (Figure 1). The two coders agreed on the selection 
of 213 articles as potentially relevant (Cohen’s Kappa = .60). The third coder reviewed 235 
disagreements and selected 86 additional articles. Thus, 299 articles were reviewed to confirm they fulfil 
all inclusion criteria; 213 were excluded based on title and abstract, and 35 after full manuscript 
examination.  Finally, 51 studies were included in the review. Reasons for exclusion are detailed in 
Figure 1. 
_______ 
INSERT Figure 1 ABOUT HERE 
_______ 
Study characteristics 
Characteristics of studies are showed in Table 1. Most studies were conducted in European countries 
(n=21) or the United States (n=19). Settings of studies were diverse: primary and secondary care, 
pharmacies, general population, and various prescription and insurance claims databases. Eleven studies 
used existing databases, while 40 studies collected data directly from patients. Thirty two studies 
focused solely on adults (>18 years), while 19 studies included adults and children. Sample sizes ranged 
from 34 to 292738 participants (median 204, interquartile range 906). Most studies included more 
women than men. Asthma severity was reported in 16 studies and ranged from mild to severe asthma.
Table 1. Study characteristics of empirical studies on inhaled medication adherence in adults with asthma (chronological order) 
 First 
author, 
publication 
year 
(country) 
Objectives 
Study 
design 
Data sources 
Sample 
size 
Age, years 
- mean 
(SD) 
[range] 
Female 
gender 
- count 
(%)  
Asthma 
severity 
- FEV1% 
Inhaled 
medication 
Tettersell, 
1993 (UK) 
(33)  
Relationship between knowledge and treatment 
adherence 
CS 
(ASD) 
Primary care 100 50.1(20.6) 9% Moderate 
to severe 
NR 
Bosley, 
1995 (UK) 
(34) 
Psychological factors related to asthma self-care 
and compliance 
PC 
(DPA) 
Primary care & 
outpatient clinic 
72 45 (15) 62 NR ICs+LABA 
ICs/LABA 
Apter, 1998 
(US) (35) 
Patient characteristics related to adherence to 
twice daily ICs treatment 
PC (DPA 
& ASD) 
Outpatient clinics 50 46 (14) 37 (74) 75% ± 
21% 
ICs 
Bennett, 
1998 (UK) 
(36) 
Associations between protection motivation theory 
factors (health threat, outcome, self-efficacy) and 
adherence to preventive ICs use 
CS 
(ASD) 
Primary care 71 47 (19.25) 40 NR NR ICs 
Chambers, 
1999 (US) 
(37) 
Factors associated with regular ICs use CS 
(ASD) 
Primary care 394 36 median (75) NR ICs 
Schmaling, 
2000 (US) 
(38) 
Development of measures to assess psychological 
factors important  to adherence with medication 
regimens 
CS 
(ASD) 
Private asthma 
clinic & hospital 
53 36.1 (9.6) (62.3) NR ICs, LABA, 
SABA 
Horne , 
2002 (UK) 
Relation between reported adherence to preventer 
medication and perceptions  and asthma 
CS 
(ASD) 
Primary care 100 49.3 (18.1) (61) NR NR 
(39) medication 
van 
Schayck, 
2002 (NL) 
(40) 
Influence of inhalation device, patients’ inhaler 
perceptions, daily frequency, and duration of 
treatment on medication compliance 
PC (DPA 
& ASD) 
Primary care 34 37 (13) 19 NR LABA or 
SABA 
Apter, 2003 
(US) (41) 
Barriers to adherence as explanations of racial-
ethnic differences in adherence 
PC (DPA 
& ASD) 
Primary & 
secondary care 
85 47 (15) 61 (72) 65% ± 
19% 
ICs 
Jessop, 
2003 (UK) 
(42) 
Relation between cognitive and emotional 
representations of asthma and adherence to 
inhaled preventative asthma medication 
CS 
(ASD) 
Primary care 330 57.2 (17.9) 204 
(61.8) 
NR NR 
Labrecque, 
2003 (CA) 
(43) 
Assess compliance to asthma guidelines and 
influence of age on SABA utilization 
RC 
(ASD) 
Health insurance 
database claims 
987(394+
593) 
[5-45] NR severe 
asthma 
excluded 
SABA (with 
or without 
ICs) 
Nishiyama, 
2003 (UK) 
(44) 
Determine if the Jones Morbidity Index can be 
used in community pharmacy to identify those who 
have poor control 
CS 
(ASD) 
Pharmacy 
database 
306  38.5 
(20.6) 
(54.5) NR ICs and 
SABA 
Balkrishnan, 
2005 (US) 
(45) 
Asthma-related health care costs and medication 
adherence  ICs and newly started on MON versus 
salmeterol (SAL) 
RC 
(DPA) 
Health insurance 
database claims 
198  22 (19.5) 
MON; 24 
(18.2) SAL 
(52.5) 
MON;  
(59.8) 
SAL  
NR ICs+LABA 
vs ICs+MON  
Lacasse, 
2005 (CA) 
(46) 
Describe patterns of compliance and identify 
factors determining the compliance to ICs in adults 
PC (DPA 
& ASD) 
NR 124 47 (15) 73 Mild-
moderate  
ICs 
Stempel, 
2005 (US) 
Patient adherence with several medication 
regimens: FP/SAL, FP+SAL, FP+MON, FP, MON 
RC 
(ASD) 
Health insurance 
database claims 
3503 38.7 (17) (64.5) NR ICs, LABA, 
MON 
(47) 
Bender, 
2006 (US) 
(48) 
Factors related to refill adherence to FP/SAL RC 
(ASD) 
Pharmacy 
database 
5504 54 (22) (60.2) NR ICs/LABA 
Chatkin, 
2006 (BR) 
(49) 
Rate of compliance with preventive treatment for 
moderate and severe persistent asthma 
PC 
(DPA) 
Primary care 131 44.4 (16.6) (71) severe 
persistent  
ICs/LABA 
Hasegawa, 
2006 (JA) 
(50) 
Comparison between compliance to fluticasone 
propionate diskus (FPdk) versus diskhaler (FPdh) 
RC 
(ASD) 
Pharmacy 
database 
337 54.2 (16.8) 
FPdh; 57.7 
(18.2) 
FPdk 
(56.3) 
FPdh; 
(57) 
FPdk 
NR ICs 
Marceau, 
2006 (CA) 
(51) 
Compare persistence, adherence, and 
effectiveness between patients with asthma 
starting combination or concurrent therapies (ICs 
and LABA). 
PC (DPA 
& ASD) 
Health insurance 
database claims 
5118 32.6 ( 8.2) (63,3) NR ICs/LABA vs 
ICs + LABA 
Ohm, 2006 
(US) (52) 
Explore asthma symptom perception and its 
relationship with adherence to asthma treatment 
CS 
(ASD) 
asthma/allergy 
clinics 
120 44.8 (9.27) (78) mild to 
severe  
ICs 
Tavasoli, 
2006 (IR) 
(53) 
Factors related to patients' compliance with 
prescribed Metered Dose Inhaler drugs 
CS 
(ASD) 
outpatient 
department 
160 47.67 
(12.78) 
105 
(65,6) 
NR ICs, LABA, 
SABA 
Ulrik, 2006 
(DNK) (54) 
Patient-related aspects of adherence among adult 
asthmatics 
CS 
(ASD) 
Community (web-
based panel for 
market research) 
509 [18-45] 317 
(62) 
mild 77%, 
moderate 
12% 
severe 
11% 
ICs, 
ICs+LABA 
Williams, Factors associated with ICs adherence among RC Health 176 40.8 (7.7) 115 NR ICs 
Joseph, 
Peterson, 
Moon, 2007 
(US) (55) 
patients with asthma, and among African 
American and white patients separately 
(ASD) maintenance 
organization 
(68,1) 
Williams, 
Joseph, 
Peterson, 
Wells, 2007 
(US) (56) 
Estimate rates of primary non-adherence and 
explore associated factors 
RC 
(ASD) 
Health 
maintenance 
organization 
1064 31.9 (16.5) (59,8) NR ICs 
Breekveldt-
Postma, 
2008 (NL) 
(57) 
Determinants of persistence with ICs PC 
(DPA) 
Pharmacy 
database 
5563 [0-34] (51.5) – 
(57.2)  
NR ICs, 
ICs+LABA 
Janson, 
2008 (US) 
(58) 
Describe asthma medication adherence, identify 
predictors of ICs underuse and SABA or LABA 
overuse 
CS (DPA 
& ASD) 
Primary & 
secondary care 
(random-digit 
dialling) 
158 48.7 (7.4) 
46.7 (8.5) 
46.5 (8.8) 
46.2 (7.3) 
(68) NR ICs and 
SABA or 
LABA 
Martínez-
Moragón, 
2008 (SP) 
(59) 
Relationship between failure to perceive dyspnea 
associated with bronchial obstruction and 
treatment non-adherence in asthmatic patients 
CS 
(ASD) 
Outpatient 
respiratory clinics 
48 48(14) 
44(15) 
(50) moderate ICs/LABA 
McGann, 
2008 (US) 
(60) 
Relationship between denial of illness and 
compliance with inhaled controller asthma 
medications 
PC 
(DPA) 
Asthma clinics, 
advertisements, 
local college 
51 42 (14.99); 
[18-68] 
(82.3) NR NR 
(controller) 
Menckeberg
, 2008 (NL) 
(61) 
Relationship between beliefs about ICs (necessity 
and concerns) and adherence 
CS/RC 
(ASD) 
Pharmacy 
database 
238 36.2 (6.3) 
 
(67) NR ICs 
Wells, 2008 
(US) (62) 
Factors that contribute to ICs adherence among 
African-American and white adults with asthma 
RC 
(ASD) 
Health 
maintenance 
organization  
1006 43.1 (10.4) 716 
(71.2) 
NR ICs 
Axelsson, 
2009 (SWE) 
(63) 
Personality traits related to asthma control, health-
related quality of life and adherence to regular 
asthma medication 
CS 
(ASD) 
Epidemiological 
study 
109 [21-23] (61.6)  NR ICs/LABA, 
ICs; LABA; 
SABA 
Bae, 2009 
(KO) (64) 
Baseline information about ICs adherence in 
Korea; factors related to ICs adherence; clinical 
implications of ICs adherence for asthma control 
CS/RC 
(ASD) 
Clinical centres in 
university 
hospitals 
185 NR NR NR ICs or 
ICs/LABA 
Laforest, 
2009 (FR) 
(65) 
Characteristics of patients with interruptions of 
ICs, intentional or accidental 
CS 
(ASD) 
Primary care 
database 
204 53.8 (19.6) (59.3) all ranges ICs only or in 
combination 
Ponieman, 
2009 (US) 
(66) 
Impact of potentially modifiable medication beliefs 
on adherence with ICs therapy across time. 
PC (DPA 
& ASD) 
General internal 
medicine clinics 
261 48 (13) 
 [20-87] 
(82) persistent 
asthma 
ICs 
Friedman, 
2010 (US) 
(67) 
Adherence and asthma control in adolescents and 
young adults with mild asthma who began 
treatment with mometasone furoate (MF) or FP 
RC(ASD) Health insurance 
claims database 
1384 16.3 MF; 
16.5 FP; 
[12-25] 
(51.3) 
MF; 
(55.3) 
FP 
mild ICs 
Takemura, 
2010 (JA) 
(68) 
Assess factors and mechanisms that contribute to 
and clinical outcomes relating to adherence 
CS 
(ASD) 
Respiratory clinic 176 57 (15) 89 NR ICs, 
ICs/LABA 
Bolman, 
2011 (NL) 
(69) 
Explain ICs adherence by the attitude, social 
influence and self-efficacy model and habit 
strength (moderation and mediation relationships) 
CS 
(ASD) 
Pharmacy 139 31.5  (5.6) 98 
(70.5) 
NR ICs 
Emilsson, Influence of personality traits and beliefs about CS NR 35 52.8 (14.7) 25 NR ICs/LABA; 
2011 (SWE) 
(70) 
medicines on asthma medication adherence (ASD) ICs+LABA; 
ICs; LABA 
Small, 
2011(UK) 
(71) 
Relationship between inhaler satisfaction and 
patient compliance. Influence on health and 
patient-reported outcomes 
CS 
(ASD) 
Specialists' and 
primary care 
2135 NR (adults) NR NR NR 
Suzuki, 
2011 (JA) 
(72) 
Associations between several factors of asthma 
therapy (patients adherence, asthma severity) 
RC(ASD) University 
Hospital 
50 36.3 (7.9)  (46) NR ICs 
Foster, 2012 
(AU) (73) 
Identify potentially modifiable beliefs and 
behaviours that predict ICs/LABA adherence 
PC 
(ASD) 
Community 
pharmacies, 
advertising, 
primary care, 
volunteer 
database 
99 47.6 (15.8) 57 83% ± 
23% 
ICs/LABA 
Ahmedani, 
2013 (US) 
(74) 
Relationships between locus of control factors 
(God, doctors, other people, change and internal) 
and ICs adherence 
CS 
(ASD) 
Primary care 1025 37.6 (14.8) 675 
(65.9) 
NR ICs 
Axelsson, 
2013 (SWE) 
(75) 
To determine the mediating effects of medication 
beliefs between personality traits and adherence 
CS 
(ASD) 
Community 516 47.4 (15.6) (60) NR ICs/LABA, 
ICs; LABA; 
SABA 
Price, Lee, 
2013 (UK) 
(76) 
Identify characteristics of patients who prefer 
once-daily controller regimen 
RC 
(ASD) 
Primary care 
database 
3731 45.6 (15) 
[2-94] 
2174 
(58.3) 
NR ICs; 
ICs+LABA 
Price, 
Thomas, 
2013 (UK) 
(77) 
Compare real life effectiveness of extrafine and 
larger particle beclometasone 
C-C 
(DPA) 
Primary care 
databases 
30354 [12-80] 17808 
(58.7%) 
NR ICs 
Schatz, 
2013 (US) 
(78) 
Develop a questionnaire that reflects 
nonadherence risk and identifies adherence 
barriers 
PC (DPA 
& ASD) 
Health 
maintenance 
organization 
420 41.6 (9.1) 280 
(66.7) 
NR ICs; SABA 
Wells, 2013 
(US) (79) 
Determine whether once daily dosing is 
associated with higher ICs adherence than 2 or 
more times daily dosing 
RC 
(DPA) 
Health 
maintenance 
organization 
1302 28.2 (15.8) 
once daily; 
31.6 (16.0) 
≥ 2 daily 
113 
(51.1) 
once 
daily; 
656 
(60.7) ≥ 
2 daily 
Low to 
severe 
ICs 
Baddar, 
2014 
(Oman) (80) 
Relationships between patient compliance, inhaler 
technique and asthma control level 
CS 
(ASD) 
University 
Hospital 
218 [12-72] (65.1) NR ICs; 
ICs/LABA; 
ICs+LABA 
Federman, 
2014 (US) 
(81) 
Associations of self-management behaviours (e.g. 
medication adherence and inhaler technique) with 
health literacy 
PC 
(DPA) 
Outpatient clinics 433 67; 45% 
60-64, 
39% 65-
74, 16% 
≥75 
(83.8) Moderate 
or severe 
ICs only or in 
combination 
Taylor, 2014 
(UK) (82) 
To develop an annual measure of ICs adherence 
from prescribing data and statistically model ICs 
adherence controlling for patient factors 
RC 
(DPA) 
Primary care 
database 
292738 38.7 (15.4) NR BTS/SIGN 
step 2-5 
ICs 
Van Steenis, 
2014 (NL) 
(83) 
Relationship between ICs necessity and concerns 
beliefs and subjectively- and objectively-measured 
adherence and the agreement between these 
measures 
CS 
(ASD) 
Pharmacy 93 43.7 (14.5) 
[18-77] 
55 
(59.1) 
NR ICs only or in 
combination 
Note: Abbreviations are: SD: standard deviation; FEV1%: forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity; NR: not 
reported; for country: UK: United Kingdom; US: United States; NL: Netherlands; CA: Canada; BR: Brazil; JA: Japan; IR: Ireland; DNK: Denmark; SP: Spain; SWE: 
Sweden; KO: South Korea; FR: France; AU: Australia; for study design: CS:  Cross- sectional; RC: Retrospective Cohort; C-C: case-control study; PC: Prospective cohort; 
ASD: adherence simultaneous with determinants measurement; DPA: determinants preceding adherence measurement; for asthma severity: BTS/SIGN: British Thoracic 
Society/Scottish Intercollegiate Guidelines Network; for medication: SABA: short-acting beta2- agonists; LABA: long-acting beta2-agonists; ICs: inhaled corticosteroids.
Twenty studies focused on adherence to ICs only, eight assessed adherence to inhaled asthma 
medication as a generic treatment category, and 23 studies focused on various types of medication, 
including ICs and long- or short-acting beta-agonists (LABA and SABA), either in monotherapy or in fixed 
(ICs/LABA) or free (ICs+LABA) combinations. Two studies analysed repeated measures of adherence in 
longitudinal cohort designs, prospectively (66) or retrospectively (82). All other studies collected data 
cross-sectionally, retrospectively, or prospectively (22, 16, and 12 studies respectively) and analysed 
relationships between determinants and single adherence measures.  
There were substantial differences between studies in operationalization and measurement of 
both adherence determinants and behaviours (see Supplementary Material 3). Of the 68 adherence 
behaviour assessments (several studies used multiple measures; see Table 2), 31 relied on patient 
reports, 24 accessed medical records (prescription and refill data), seven employed electronic 
monitoring, four used canister weighting, one used dose counters, and one requested physician reports. 
Fifteen of the patient-reported adherence assessments applied validated questionnaires like the 
Medication Adherence Rating Scale (MARS (39) and Revised Asthma Adherence Scale (RAAS (84), while 
the remainder used self-constructed non-validated questionnaires.  
 
 Table 2. Definition and measurement of adherence behaviours in the studies reviewed (chronological order). 
First author, 
publication 
year 
Adherence definition/ term 
Assessment 
method 
Details 
Validity/ 
reliability 
Tettersell 
1993 
taking inhalers as prescribed patient-report, 
single item 
1 item: “Do you take your inhalers as prescribed?”;  4 response options: 
“Always”, “Majority of the time (8 out of 10 doses)”, “About half of the time”, 
“Only during or following an attack” 
NR 
Bosley, 1995 noncompliance; taking less than 
70% of prescribed doses or omitting 
all doses for 1 week or more 
electronic 
monitoring 
Turbohaler Inhalation Computer; computed for two 6-week periods as (no of 
doses taken)/(no of doses prescribed)*100 
NR 
Apter, 1998 use of ICs in the last 35 days  electronic 
monitoring 
MDILog, last 35 of 42 days considered, computed for 12-hour periods as 
(recorded - prescribed actuations)*100; mean truncated adherence computed 
per subject; dichotomized (< or >70%) 
NR 
Bennett, 
1998 
adherence to preventive ICs use patient-report, 
published 
scale 
RAAS (84)  α .75 
Chambers, 
1999 
frequency of ICs use patient-report, 
single item 
Item content not specified; 4 response options: “I use it at least twice a day 
almost every day”, “Some days I use it at least twice, but on other days I 
don’t use it at all”, I used to use it, but now I don’t”, “I never used it”; 
dichotomized into 'regular, twice daily' and 'less than regular' 
NR 
Schmaling, 
2000 
as-needed medication use canister 
weighting 
total number of medication inhalations for each day in the prescription period NR 
daily medication adherence canister 
weighting 
predicted use (no. days * no. puff per day) compared to actual use; computed 
as percent of prescribed medication used 
NR 
Horne, 2002 medication adherence patient-report, 
published 
MARS (39)  α .85 
scale 
van 
Schayck, 
2002 
medication compliance rate canister 
weighting 
medication used as a percentage of medication prescribed NR 
Apter, 2003 use of ICs in the last 42 days electronic 
monitoring 
MDILog, 42 days, computed for 12-hour periods as (recorded - prescribed 
actuations)*100; mean truncated adherence computed per subject; divided 
into 4 categories (<20%, 20-<50%, 50-<75%, 75%-100%) 
NR 
Jessop, 
2003 
adherence to preventative inhaled 
medication in the last 3 months 
patient-report, 
published 
scale 
(adapted) 
RAAS (84) and two extra items on accidental non-adherence  α .92 
Labrecque, 
2003 
conformity of SABA prescription use 
with accepted good use criteria 
medical (refill) 
records 
dichotomous; good use criteria: for SABA with no ICs use, the interval 
between the targeted SABA prescription and the following refill corresponds 
to a maximum daily use of two inhalations; for SABA with ICs use, the 
criterion above, and a daily ICs dose below a fixed threshold  
NR 
Nishiyama, 
2003 
reliever compliance patient-report, 
interview 
patients were required to state the drugs and dosage regimens they used; 
their reports were compared with prescription information; 3 values coded: 
“good’’; “overused”; “underused” (first two applied also to reliever) 
NR 
preventer compliance patient-report, 
interview 
NR 
Balkrishnan, 
2005 
adherence to controller 
pharmacotherapy 
medical (refill) 
records 
computed as (days of prescription supply dispensed)/(days between 
prescription refills - number of days person was hospitalized); dichotomized 
as compliant (0.5-1.5) or not 
NR 
Lacasse, 
2005 
non-compliance electronic 
monitoring 
MDILog; calculated for 12 weeks daily as proportion of prescribed daily dose 
actually inhaled; dichotomised as compliant (>75%) or not 
NR 
Stempel, 
2005 
asthma medication refill rate medical (refill) 
records 
number of 1-month supply during the 12-month post-index period  NR 
number of treatment days medical (refill) 
records 
For monotherapy: total days supplied of medication; for combination: total 
days supplied of ICs 
NR 
SABA refill rates medical (refill) 
records 
number of 1-month supply during the 12-month post-index period NR 
Bender, 
2006 
adherence to ICs/LABA medical (refill) 
records 
total days supplied during follow-up period NR 
persistence medical (refill) 
records 
time to discontinuation computed as number of days from index date to date 
preceding the pre-specified gap when supply was exhausted  
NR 
Chatkin, 
2006 
compliance canister 
weighting 
(total quantity of medication used )/ (quantity prescribed, i.e. 3 canisters in 3 
months); dichotomised as compliant (>85%) or not 
NR 
Hasegawa, 
2006 
drug compliance medical 
(prescription 
and refill) 
records  
computed for 6 months as (number of medicines dispensed)/(number of 
medicines prescribed)*100; capped at 100% 
NR 
Marceau, 
2006 
persistence versus discontinuation - 
having prescriptions continuously 
renewed within the period 
medical (refill) 
records 
computed as the sum of 3 times the duration of the current prescription (in 
days) plus all overlaps accumulated since therapy start; discontinuation date 
was the end date of the last filled prescription plus all overlaps 
NR 
Ohm, 2006 
 
use of ICs+LABA electronic 
monitoring 
Advair diskhaler; computed as (number of counted doses)/(number of 
prescribed doses)*100. Dichotomized as good adherence (≥80%) or not 
NR 
medication adherence patient-report, 
published 
scale 
MARS (39) NR 
Tavasoli, 
2006 
compliance to prescribed MDI drugs patient-report, 
interview 
4 items: "Do you use your prescribed spray (MDI drug) regularly?", "Have 
you ever had any history of not using your spray?", "Do you still use your last 
prescribed spray?", "How do you use your spray? Show me"; response 
scales from 0 to 4 
NR 
Ulrik, 2006 intentional non-adherence patient-report, 
single item 
1 item: “How often do you decide not to take your controller medication?”; 5 
response options: “almost every day”, “a couple of times every week”, “a 
couple of times every month”, “a couple of times every year”, “hardly ever” 
NR 
adherence patient-report, item not specified; responses reported on a 3-level scale: taking controller NR 
single item therapy as prescribed, less, or more than prescribed 
Williams, 
Joseph, 
Peterson, 
Moon, 2007 
ICs adherence medical (refill) 
records 
(cumulative days supplied )/ (total number of days between refills for 1-year 
study period); analyses performed also with adherence stratified (0%, 0-80%, 
≥80%) 
NR 
Williams, 
Joseph, 
Peterson,  
Wells, 2007 
primary non-adherence medical (refill) 
records 
no prescription fill information recorded for 3 months after index prescription NR 
ICs adherence medical (refill) 
records 
computed as (total days supplied)/(number of days of observation)*100; 
adherence stratified (0%, 0-80%, ≥80%) 
NR 
Breekveldt-
Postma, 
2008 
persistence during the first year;  medical (refill) 
records 
computed as number of days from start to time of first failure to continue 
renewal of initial prescription, based on (number of units dispensed)/(number 
of units to be used per day as defined in pharmacy) 
NR 
Janson, 
2008 
ICs nonadherence during the last 14 
days 
patient-report, 
interview 
nurse home assessment of ICs prescription and use, based on inspection of 
current asthma medication and 2 questions: “How many puffs and how many 
times per day did your doctor tell you to use this?”, “During the past 14 days, 
how many puffs and how many times per day have you used this?”; 
dichotomized as adherent (≥7 days of use in previous 14 days) or not 
NR 
SABA or LABA overuse patient-report, 
interview 
nurse home assessment on SABA and LABA prescription and use, 
dichotomized as overuse (average >8 puffs of SABA or >2 puffs of LABA -
single or combination- per day) or adherent  
NR 
Martínez-
Moragón, 
2008 
frequency of ICs use patient-report, 
single item 
1 item, not specified, adapted after (37); 4 response options, from “never” to 
“at least twice a day almost every day”, dichotomized into “almost every day” 
versus “rarely if ever” 
NR 
McGann, 
2008 
"how closely an individual’s 
medication-taking behaviors, as 
measured by the DOSER, 
approximated prescribed use 
instructions provided by the health 
care provider"  
electronic 
monitoring 
DOSER; ratio of the number of observed correct prescribed use days 
between day 3 and 14 
agreement 
with other 
measures 
(not 
specified) 
84.32% 
Menckeberg, 
2008 
medication acquisition medical (refill) 
records 
(total days supplied) /(total number of days from first and last refill date)*100  
medication adherence patient-report, 
published 
scale 
MARS (39)  α .81 
Wells, 2008 ICs adherence; the proportion of 
time that the patient had medication 
available during last 6 months 
medical (refill) 
records 
(total days supplied)/(number of days of observation)*100 NR 
Axelsson, 
2009 
medication adherence patient-report, 
published 
scale 
MARS (39)  α .71 
Bae, 2009 prescription refill adherence medical (refill) 
records 
 (number of ICs refills)/12*100; categorized as appropriate use (>80%), 
underuse (50-80%), or extreme underuse (<50%) 
NR 
subjective self-reported adherence patient-report, 
single item 
1 item: “How often did you take your ICs as prescribed for last 1 year?”; 
response on a visual analogue scale from 0% to 100%; categorized as 
appropriate use (>80%), under-use (50-80%), and extreme under-use 
(<50%) 
NR 
Laforest, 
2009 
Intentional interruption 
 
patient-report, 
single item 
Six items included: (1) accidental interruption, (2) intentional interruption 
when feeling better, (3) intentional interruption when feeling worse, (4) 
reduced use when feeling better, (5) more frequent use of ICs in case of 
preliminary signs of asthma attack and (6) intentional changes of doses 
independently of physician; analyses performed on intentional (when feeling 
better) and accidental interruption.  
NR 
Accidental interruption patient-report, 
single item 
Ponieman, 
2009 
medication adherence patient-report, 
published 
scale 
MARS (39); dichotomised as good adherence (≥ 4.5) or not  α .86 
Friedman, 
2010 
prescription fills medical (refill) 
records 
total number of prescription refills during the post-index period NR 
percentage days covered medical (refill) 
records 
(number of days patients had medication on hand)/(total number of post-
index days = 365)*100 
NR 
Takemura, 
2010 
self-reported adherence to inhalation 
regimen 
patient-report, 
published 
scale 
(adapted) 
modification of RAAS (84) concerning the use of inhaled controller 
medications; mean adherence score computed; dichotomized  as good 
adherence (≥4.0) or not 
NR 
Bolman, 
2011 
medication adherence patient-report, 
published 
scale 
MARS (39)  α .89 
Emilsson, 
2011 
medication adherence patient-report, 
published 
scale 
MARS (39)  α .77 
Small, 2011 physician-perceived compliance; 
“the extent to which the patients are 
perceived to follow their physician’s 
prescribing instructions and advice” 
physician-
report, 
bespoke scale 
2 items (not specified) on physician-perceived patients’ compliance regarding 
frequency of use and inhaler use; 5 response options from 'not at all 
compliant' to 'fully compliant' 
 α .92 
Suzuki, 2011 ICs adherence medical 
(prescription 
and refill) 
records 
ratio of doses dispensed in the pharmacy divided by prescribed doses 
documented in medical charts 
NR 
Foster  2012  Adherence with ICs/LABA electronic 
monitoring 
Smartinhaler; daily adherence calculated as (no. recorded actuations/no puffs 
prescribed)*100, capped at 100% and averaged for the last 4 weeks of 2 
months monitored  
NR 
  patient-report, 
published 
scale 
Morisky adherence scale [ref] NR 
  patient-report, 
single item 
Estimation of own inhaler use (days/week and puff/day) in the last 4 weeks NR 
Ahmedani, ICs adherence medical (total days supplied)/(3-month observation period)*100 NR 
2013  (prescription 
and refill) 
records 
Axelsson, 
Cliffordson, 
2013 
medication adherence patient-report, 
published 
scale 
MARS (39)MARS (39)  α .75 
Price, Lee, 
2013  
ICs adherence patient-report, 
published 
scale 
MARS (39), categorized as ‘low’(´often´ or ´always´ response to any 
question), ‘borderline’ (´sometimes´ responses to > 1 question), and ‘good’ 
(any other answer)MARS (39), categorized as ‘low’(´often´ or ´always´ 
response to any question), ‘borderline’ (´sometimes´ responses to > 1 
question), and ‘good’ (any other answer) 
NR 
Price, 
Thomas 
2013  
ICs adherence Medical 
(prescription) 
records 
(total days supplied)/(365-day observation period)*100 NR 
Schatz, 2013  Questionnaire low adherence patient-report, 
published 
scale 
Response to ‘how often are you actually taking your IC medication now’ 
compared to response to ‘based on your doctor’s most recent instructions, 
how often were you advised to be taking your IC medication now’ (less 
frequently) 
NR 
 Percent of days covered Medical (refill) 
records 
Days’ supply of dispensed canisters over the follow-up at 3, 6, and 12 months NR 
Wells, 2013  ICs adherence medical 
(prescription 
and refill) 
records 
Continuous multiple-interval measure of medication availability = number of 
days’ supply for each fill/total number of days between the present and next 
fill; averaged for the observation period 
NR 
Baddar, 
2014  
Compliance with controller treatment Interview 
cross-checked 
with electronic 
patient records 
Good = taking 100% of daily prescribed medication & ≤ 2 missed 
doses/administrations per week; partial = taking more or less than their daily 
prescribed medication; poor = any other inhaler use patterns 
NR 
Federman, ICs adherence Dose count Review of dose counters for all dry powder inhaler devices during the first 3 NR 
2014 [ref] months and 30 days after each new prescription; dichotomized as < and 
≥80% 
Taylor, 2014  Adherence to ICs prescriptions Medical 
(prescription) 
records 
Prescription possession ratio = (number of days prescribed during calendar 
year)/(number of days in the interval)*100 
NR 
van Steenis, 
2014  
ICs adherence patient-report, 
published 
scale 
(adapted) 
Morisky adherence scale [ref], adapted NR 
 ICs adherence Medical (refill) 
records 
Proportion of days covered = (number of days supply)/(365 or truncated if 
medication gap ≥ 182)*100; dichotomized as < and ≥80% 
NR 
Note: Abbreviations are: ICs: inhaled corticosteroids; LABA: long-acting beta2-agonists; SABA: short-acting beta2- agonists; MDI: metered-dose inhaler; RAAS: Revised 
Asthma Adherence Scale; MARS: Medication Adherence Rating Scale; NR: not reported; α: Cronbach’s α test. 
As most results focused on implementation of controller medication, we chose to summarize these both 
graphically and in text (Figures 2 and 3). The results on controller initiation and persistence and on 
reliever use were limited and therefore only described textually.   
Determinants of controller medication adherence 
 
Initiation: Determinants of controller initiation were examined in one study (56) that reported a higher 
probability of non-initiation for patients of younger age, female, of African-American ethnicity (versus 
white), and with fewer SABA fills in the preceding year. No associations were found with socio-economic 
status, comorbidity, costs of treatment, and various health care utilisation indicators.  
 
Implementation: We identified 544 results in 47 studies, of which 457 relationships between a 
determinant and an adherence measure could be assessed in terms of significance and direction of 
relationship. Figures 2 provides details on the WHO determinant sub-dimensions with at least three 
results; as different measures of adherence may lead to different associations with determinants, we 
distinguished between objective measures, medical records, and subjective reports with each type of 
measure. Results from higher quality studies are presented separately in Figure 3. Determinants with 
less than three results are described briefly only in text. 
 
_______ 
INSERT Figure 2 ABOUT HERE 
_______ 
 
_______ 
INSERT Figure 3 ABOUT HERE 
_______ 
 
Social and economic factors were investigated in 15 studies. Higher income was related to 
adherence in three of eight results reported (35,41,54–56,58–60), more prescription coverage in one of 
four results (35,41,46,60), lower treatment costs in two of seven results (48,55,56,62,78), and less 
perceived social norms in one of three results (69,73,78). Several other variables were reported as 
unrelated to adherence less than three studies: geographical area (48), urban location (60), immigration 
status (53), crime rate in area of residence (55), social modelling (69), and social support (41,69). 
Minority status was related to adherence in one study (35), and employment status in one of two 
studies (53,60).  
Eight studies examined health care team and system factors, with education provision relating 
to adherence in three of four results (33,46,68). Several other variables were examined in less than 
three studies: lower adherence was linked to inability to get an appointment when needed in one study 
(62), to patient-provider communication in one of two studies (35,41), and to the time interval being 
registered with the same prescriber in one study (82), while receiving a prescription from a specialist 
versus a generalist was unrelated to adherence (60).  
Therapy-related factors were investigated in 18 studies. Adherence was mostly unrelated to the 
number of drugs in the treatment regimen (three of four results; (64,71,79), the number of daily doses 
(five of seven results; (40,48,65,68,79), and having reliever inhalers prescribed (four of five results; 
(35,48,49,65). Using dry-powder versus metered-dose inhalers (DPIs and MDIs) was linked to adherence 
in two of four results (67,68). Some variables examined in a single study were unrelated to adherence: 
prescribed use of peak flow meter or action plan (46), treatment duration (68), using various other drugs 
(45,49,53,58,65), using autohalers versus other MDIs (40). Other single-study variables were related to 
higher adherence: using diskus DPIs versus diskhaler DPIs (50), using ultrafine versus large-particle 
formulation (77), not using a spacer (53), and receiving more refills in a prescription (48). Three studies 
have compared ICs/LABA regimens with different types of alternative regimens and reported better 
adherence to ICs/LABA compared to ICs and/or LABA and/or SABA (63), and compared to ICs in 
monotherapy or in combination with LABA or montelukast (47), but no differences in intentional or 
accidental non-adherence between ICs/LABA and ICs+LABA regimens (65).  
Condition-related factors were investigated in 26 studies, with non-significant results regarding 
asthma duration (nine results (35,36,39,42,46,53,62,68), pulmonary function (six of eight results; 
(35,41,46,52,58,59), and presence of current symptoms (19 of 22 results; 
(35,36,42,44,46,49,53,58,59,62,63,65,71,80,83). Asthma exacerbations showed 13 non-significant 
(35,41,49,56,58,68,74,82), but also five positive (37,56,74,82) and six negative associations (53,68,71) 
with adherence. Higher health-related quality of life was associated with better adherence in four of 11 
results (46,58,63,65,68,71), and higher asthma severity was linked to better adherence in five results 
(49,69,72,79,82), compared to one negative (82) and 6 nonsignificant results (41,53,65,71,72) 
Patient-related factors were investigated in 40 studies. Patient demographics such as age and 
gender were included in numerous studies. Older age related to better adherence in 16 of 28 results 
(33,35,36,39,41,42,46,48,53–56,58,59,62,64,65,68,70,71,73,74,79,82,83). Gender showed 24 non-
significant results (35,39,41,42,46,48,49,53–56,58–60,62–65,68,69,71,72,74,80,83), females showing 
better adherence in three results (42,48,54) and males in other three (62,73,79). Being of white ethnicity 
was linked with better adherence in five of ten results (41,49,55,56,58,60,62,71,74,79), while 
participants with higher education levels were more adherent in four of ten results 
(35,39,41,46,49,53,54,58–60).  
Few studies found significant roles of variables related to patients’ general health status. 
Smoking status was consistently unrelated to adherence (41,49,53,58,59,64,65,72), as was depression 
(41,46,58,59). Higher comorbidity was associated with better adherence in two of eight results 
(48,49,55,56,58,64), while less health care utilisation was linked to better adherence in two of 11 results 
(35,39,41,56,71). Asthma knowledge was found unrelated to adherence (33,54), while medication 
knowledge was reported as related to adherence only in one of five results (35,41,62,78). Asthma beliefs 
(i.e. perceptions of the asthma impact in terms of severity, consequences, timeline, etc.) showed 
inconsistent relations with adherence, with eight positive (36,37,42,54,73), ten nonsignificant 
(36,39,42,54,58,59), and one negative result (39).  
The role of treatment beliefs was studied extensively. Stronger beliefs in the necessity of using 
inhalers were associated with better adherence in 14 of 16 results (39,41,54,61,62,66,70,75,78,83), 
beliefs in their effectiveness in four of seven results (36,41,53,54,78), while more broadly-framed 
positive beliefs in inhaler usefulness or benefits in one of three results (35,35). Having fewer concerns 
about medication was related to better adherence in nine of 17 results (39,41,61,65,66,69,73,75), lower 
perceived side effects in two of four results (73,78), lower beliefs that medication in general is overused 
in one of three results (61,78), and stronger beliefs in inhaler necessity relative to concerns in two of 
three studies (69,70,73). Readiness to use inhalers showed positive associations to adherence in three 
results (38,62), indicators of self-efficacy in four of nine results (33,36,41,58,66,69) , and stronger 
adherence routines in three results (54,69,73). A better ability to perceive asthma symptom changes 
was related to adherence in three of five results (52,59), while lower confidence in the ability to monitor 
symptoms was related to adherence in one of three results (42,54).  
Numerous other patient-level variables were examined in less than three studies, most with 
nonsignificant results: general health status and body mass index (58), marital status (49), number of 
causal attributions for asthma (39), extent of attributing asthma to internal causes (42), general health 
self-efficacy (66), self-control (46), and various personality and medical history characteristics 
(35,40,46,53,59,63,69,70,72,74,75). Several exceptions referred to better adherence in people who 
consider medication as less harmful (two results; (61), display lower neuroticism, higher agreeableness 
and conscientiousness (one of two results; (70,75), and believe stronger that their asthma can be 
controlled (39,42). Several single results showed better adherence in people with a family history of 
asthma (72), asthma onset at younger age (59), lower impulsivity (63), high literacy (81). Other single 
findings suggested that more adherent people attribute their asthma more to external factors (42), 
believe that God is less in control of their health and attribute more control to physicians (74), perceive 
themselves less vulnerable to side effects, report higher intention to use inhalers (73), have better 
inhaler use skills (80), are more satisfied with the device (71), prefer to use inhalers rather than pills 
(33), have no preferences regarding daily inhaler dosage (76), believe stronger in participating actively in 
care (37), and report no symptom improvement due to herbal drugs (53).  
 
Persistence: Controller persistence determinants were investigated in three studies, and results are 
presented here per study. Patients receiving prescriptions from a specialist, using MDIs, having a lower 
dose recommended, once-daily dosing frequency, having used LABAs in the previous year, and having 
had previous asthma-related hospitalizations were more likely to persist using single ICs treatment 
during one year, while adolescents and patients with more than twice daily dosing frequency were more 
likely to discontinue (57). For ICs/LABA therapy, persistence was less likely for adults compared to 
children, for people with longer therapy duration, higher daily dose, and having used antibiotics in the 
previous year (57). Patients using ICs/LABA were more likely to persist with therapy compared to those 
using ICs+LABA, as were male patients, older, receiving social assistance, with lower daily dosage, 
receiving prescriptions from a specialist, and using more medications currently and in the previous year 
(51). Time to discontinuation of ICs/LABA therapy was longer for male patients, older, paying 
moderately for treatment, having more refills included in the first prescription,  having prescriptions also 
for other conditions, and having had relievers prescribed before study start (48). 
Determinants of reliever use 
Reliever use recommendations was examined in three studies. Reliever overuse (as indicator of non-
adherence to reliever recommendations) was linked to increased symptoms in two of three results 
(44,58), to older age in one of two results (43,58), and to lower education, higher self-perceived asthma 
severity and lower general health status in one study (58). Other factors were unrelated to overuse (e.g. 
gender, ethnicity, socio-economic status, smoking status, and various health status indicators).  
 
Study quality 
The 51 studies received relatively good quality scores regarding participant selection methods 
and measurement of variables, with 19 and 14 studies receiving the maximum score respectively (Table 
3; Supplementary Material 4). Scores were considerably lower on appropriateness of data analysis, 
measures taken to protect against bias, study size justification and clarity of definitions for the variables 
included. Common limitations in reporting patient selection were omitting methods of sampling and 
checking eligibility, and not specifying response rates. The concept definitions often overlapped with the 
description of measurement methods, or only variable labels were reported. Many studies did not 
describe measurement methods for all main variables. The majority of studies did not mention any 
source of bias, and none gave a clear sample size justification or reported optimally on study size 
decisions.  Some studies reported power computations for unspecified analyses, did not correct for 
multiple comparisons, dichotomized adherence scores without giving a valid rationale, did not control 
for potential confounders, and offered unclear descriptions of statistical procedures. Inter-rater 
agreement for the six quality rating criteria (Table 3) were poor to moderate, but all discrepancies were 
resolved through discussion between the two coders. Participant selection methods, measurement of 
variables, clarity of variable definitions, and appropriateness of analyses formed a homogenous scale, 
with a homogeneity and standard error of H(S.E.)=.64(.07). Performance on the two remaining criteria 
(addressing bias and justifying sample size) was only weakly related to the quality scores on the other 
four criteria (item properties not shown for brevity). 
 
Table 3. Study quality – frequencies and inter-rater agreement for quality criteria (N=51) 
Quality criterion 
Unknown 
(no 
description 
available) 
Low (unclear 
and/or not 
appropriate) 
Medium 
(mostly clear 
and 
appropriate, 
with few 
omissions) 
High (clear 
and 
appropriate) 
Inter-rater 
agreement 
(weighted 
Kappa) 
Participant selection 0 10 22 19 .41 
Definition of variables 2 11 35 33 .31 
Measurement of 
variables 
0 16 21 14 .38 
Addressing sources of 
bias 
27 14 8 2 .38 
Study size 29 19 5 0 .17 
Data analysis 0 24 19 8 .33 
Discussion 
This systematic review aimed to qualify and synthesize the observational evidence on determinants of 
inhaled medication adherence in adults with asthma. In the 51 studies included, patient-related factors 
associated with controller implementation were the most frequently studied, and health care team and 
system factors the least; the more robust evidence linked stronger treatment necessity beliefs to better 
implementation. The few studies assessing controller initiation and persistence mainly suggests a 
possible influence of therapy-related factors and patient demographics. Studies on reliever use were 
scarce, with reliever overuse related to several patient-related factors. This limited evidence offers only 
provisional guidance for developing inhaler adherence interventions. Furthermore, the findings 
regarding each adherence determinant and behaviour should be interpreted with caution and within 
each study context due to the heterogeneity among studies. Our review reveals important knowledge 
gaps that need to be addressed in the coming years, and also highlights crucial methodological 
limitations that can inform researchers regarding concrete steps to take for accumulating sound 
evidence in future studies. 
Regarding the results on determinants of controller use implementation, the substantial focus 
on patient-related determinants was noted in previous reviews in asthma (19,20) and in other chronic 
conditions (85–87), and reflects an interest in both identifying at-risk groups and understanding patient 
perspectives as proximal determinants of patient behaviours. Demographic and clinical characteristics 
and patients’ knowledge of asthma and of medication were generally unrelated to controller use, except 
a possible higher risk of non-adherence in younger adults. Treatment necessity beliefs were consistently 
related to better controller implementation but moderate evidence exists on the role of other positive 
treatment beliefs and of concerns. These results confirm a previous review on treatment beliefs (20) and 
support the relevance of addressing patients’ views regarding their condition and treatment in 
adherence interventions.  
Determinant categories not related to patients were substantially less studied and should be 
prioritized in future research. Condition and therapy-related factors seemed unrelated to controller 
implementation behaviours or showed inconsistent results. Among these factors, several medical 
outcomes such as asthma exacerbations, severity or symptoms showed contradictory results, suggesting 
that their relationships with adherence might vary depending on other parameters which would need 
careful examination. Despite the relevance of social and economic factors identified in previous reviews 
(85–87), only financial information was examined more extensively but showed inconsistent results. 
Limited data was available on the influence of the social environment in adults with asthma, despite the 
key role of social factors identified in children’s asthma management (19) and in adherence to other 
long-term treatments for chronic conditions in general (85,88). Health care team and system factors 
were rarely studied, although the improvement of health services for chronic conditions is currently a 
priority (89) and adherence-enhancing interventions usually include changes in the structure of health 
care delivery (10). This highlights the need for further research on the structure and content of 
adherence support in routine clinical care, which can have a major impact on patient behaviours and 
treatment success rates (90,91). Future studies could also benefit from adopting broader theoretical 
approaches that also explore factors beyond the individual patient level, such as the Precede-Proceed 
framework, which would facilitate behaviour change intervention design (92). 
The barriers to evidence consolidation identified during the present review raise an important 
question: what methodological standards would future studies apply to obtain quality evidence on 
determinants of inhaler adherence? Table 4 summarizes nine main barriers and several 
recommendations for improvement, formulated considering the existing methodological advice for 
observational research (26) and adherence research (93) in order to invite further dialogue on this topic. 
The first barrier identified was the substantial study heterogeneity, not only in sample characteristics 
but also in variable selection, definition, and measurement, study design, and statistical analyses. 
Second, the studies lacked a unifying theoretical approach which led to differences in variable selection 
and thus to many determinants being examined only in single studies, often without a theoretical 
justification. Third, the results gave limited insight regarding causal influences, as only two studies 
involved repeated measures of adherence (66,82) and only 17 studies measured determinants before 
adherence. Moreover, many studies showed limitations in the six quality criteria assessed, although 
several studies performed well (see Supplementary Material 4). To address these barriers, we endorse 
the practical recommendations provided in STROBE (26) and provide brief advice based on STROBE and 
our experience in this review. Theoretical frameworks and taxonomies of adherence behaviours and 
determinants are available (27,94,95) and should be used more extensively. Conducting research on 
common theoretical and measurement foundations would allow the field to progress from identifying 
bivariate or multivariate associations in heterogeneous prediction models towards testing more 
homogeneous and comprehensive causal models. 
Table 4. Barriers and recommendations for a solid evidence base on asthma inhaler adherence 
determinants 
Current limitations When conducting a new study… 
1. Heterogeneity in variable 
selection, definition and 
measurement, study design, 
statistical analyses  
- Consider previous similar studies when selecting determinants and 
behaviours  
- Clarify variable definitions in relation to previous studies 
- Consider using established measures of adherence behaviours and 
determinants if available  
- Consider using established study designs and data analysis methods if 
appropriate 
2. Limited theoretical basis for 
variable selection and lack of an 
integrated theoretical approach 
- Use existing behavioural theory to select variables 
- Focus on testing multi-determinant models instead of a few preferred 
determinants 
- If testing new models, clarify the choice and relations with existing theory 
3. Lack of robust study designs for 
causal inferences in most studies 
- Prioritize the use of repeated-measures longitudinal designs 
- Assess adherence determinants prior to behaviours  
- Choose time lags in which causal influence is likely 
- Control for other possible causal influences 
4. Low or medium quality of 
participant selection in some studies 
- Use prior literature to decide on clear inclusion criteria that allow 
comparisons with other studies. 
- Employ systematic procedures for participant selection 
- Report participant selection procedures clearly and completely  
5. Insufficient description of variable 
definitions and measurement 
- Provide a clear rationale and description for variables included 
- Provide comprehensive descriptions of measurement tools or methods in 
manuscript or supplementary materials 
6. Low quality of measurement - Select or develop psychometrically sound measures 
- Examine psychometrics as preliminary analyses 
- Report results of psychometric evaluation 
7. Sources of bias rarely addressed - Reflect on possible sources of bias (e.g., response, recall, surveillance bias) 
and take steps to minimize their effect 
8. Study size rarely addressed - Consider the probability of type I and type II errors given the research 
question, population, and resources available  
9. Low or medium quality of data 
analysis procedures in most studies 
- Consult methodological literature relevant for the analyses intended 
- Perform and report on preparatory analyses (e.g. missing data) 
- Do not group continuous data unless solid justification exists and analyses 
are performed with both continuous and grouped data 
- Control for possible confounders and justify their selection 
- Adjust for sampling strategy and hierarchical data structures  
 Beyond the practical recommendations for future inhaler adherence studies, our review also 
highlighted the need to develop consensus on several methodological aspects. The fact that few studies 
reported on variable definitions, sources of bias and study size suggests that many researchers might 
not be aware of their importance for observational studies. The latter two aspects were unrelated to the 
overall study quality, suggesting that even in higher-quality studies, bias and sample size are not 
systematically considered. More discussion is needed among methodologists and researchers to 
establish their relevance and specify concrete steps to implement them. These results add to previously-
expressed concerns regarding the lack of validated tools to evaluate quality in observational studies 
(23), and highlight a general need for further detailing and clarifying methodological guidelines in this 
area. Our experience with coding quality exposed the difficulties of assessing these broad criteria given 
the diversity of designs and brief descriptions permitted by space constraints. We would therefore 
encourage adherence-specific methodological guidelines that can be reported in a standard format as 
supplementary materials in published studies.  
Our review has several limitations. First, interpreting the summary based on both adjusted and 
unadjusted results requires caution, as multivariate analyses control for different sets of confounders, 
while bivariate analyses ignore any additional influences and may reflect biased relationships. We chose 
to prioritize adjusted over unadjusted data to avoid this, but we acknowledge that the findings may be 
biased and we recommend the use of theory-based models to provide more valid and replicable results. 
Second, inter-rater reliability for quality scores was low, which may reflect suboptimal study reporting, 
difficulty of applying the criteria based on the given definitions, or insufficient training of coders. 
Although the coders were able to reach consensus, these difficulties illustrate the need for more 
concrete definitions applicable across studies by coders with diverse research backgrounds. Third, we 
focused our review on developed nations, as the contribution of determinant dimensions on adherence 
may be different in developing nations, particularly regarding access to care (87) but only nineteen 
studies were excluded based on this criterion. Last, meta-analyses were not possible due to the 
substantial heterogeneity, therefore we opted for a qualitative summary and for identifying 
methodological improvements that would make future studies more amenable to meta-analytic 
approaches. 
Our findings suggest that adults with asthma implement controller use recommendations better 
if they believe stronger in the necessity of using inhalers, and possibly if they hold other positive beliefs 
and less concerns about using inhalers. Younger adult patients may be more at risk of non-adherence. 
Other patient-, condition-, and therapy-related factors are either mostly unrelated to adherence, or 
partly studied, and little is known about the role of social, economic and health care factors. Initiation 
and discontinuation of controller use, and reliever use behaviours were scarcely explored. Moreover, 
the methodological limitations identified diminish the strength of current evidence. Our key 
recommendations for further research are to improve methodology and use established theoretical 
frameworks, which should enable the development of a cumulative evidence-base of causes of non-
adherence to asthma inhalers among adults. 
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Figure 3. Determinants of controller implementation (results from higher quality studies) - number 
of positive, nonsignificant and negative relations with adherence indicators for determinants with 
three or more results identified. 
 
 
